Lai-Han Leung

Title: Innovations of Lai-Han Leung in Cancer Treatment

Introduction: Lai-Han Leung is a notable inventor based in Macao, MO, recognized for his contributions to the field of cancer treatment. His innovative approach focuses on addressing gefitinib-resistant non-small-cell lung cancer (NSCLC), a significant challenge in oncology.

Latest Patents: Lai-Han Leung holds a patent for a method aimed at treating gefitinib-resistant NSCLC. This patent describes a method that involves administering an effective amount of a resveratrol analog, specifically (Z)3,4,5,4'-tetramethoxystilbene (TMS), to patients in need. The invention also outlines a method for inducing apoptosis in gefitinib-resistant NSCLC cells by applying the resveratrol analog at an effective concentration. The mechanisms of these methods are mediated by various signaling pathways related to cell proliferation and differentiation, including mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.

Career Highlights: Lai-Han Leung is affiliated with the Macau University of Science and Technology, where he continues to advance his research in cancer therapies. His work has garnered attention for its potential impact on treatment options for patients facing resistance to conventional therapies.

Collaborations: Lai-Han collaborates with esteemed colleagues, including Xing-Xing Fan and Liang Liu, who contribute to his research endeavors and enhance the scope of his innovative projects.

Conclusion: Lai-Han Leung's work exemplifies the critical intersection of innovation and healthcare, particularly in the fight against cancer. His patented methods offer promising avenues for improving treatment outcomes for patients with gefitinib-resistant NSCLC.